Background: Although it is an effective drug for treating HIV-1 infection, the non-nucleoside RT inhibitor (NNRTI) efavirenz (EFV) elicits significant CNS adverse events (AEs) such as insomnia, headache, nausea, dizziness, cognitive impairment and depression. Currently marketed NNRTIs vary in efficacy and have varying degrees of CNS AEs. Therefore, an NNRTI with high efficacy and low potential for CNS toxicities is still needed to maximize the utility of the class.
Methods: Freely-moving rats (n=16) and monkeys (n=12) were implanted with telemeterized EEG, electromyography and electrooculogram transmitters and recorded 24hr/day. In a within-subjects cross over design, animals were dosed with 50-200mg/kg EFV (BID, PO) or vehicle for 14 days each. Recordings were analyzed for sleep/wake and qEEG spectral frequency changes. Spectral differences were also compared to our EEG data collected previously on healthy volunteers receiving EFV (600mg QD) with cognitive impairment (Simen et al, J Sleep Res 2014).
Results: In both rats and monkeys, EFV produced sedation and a significant dose-responsive qEEG signature of increased low-frequency bands (Theta-Alpha) with decreased mid-frequency bands (Sigma-Beta). This signal appeared within 1-2 days of initial exposure and diminished across the first week of treatment. Our previous healthy volunteer EFV EEG study produced a strikingly similar increase in Theta-Alpha plus decrease in Sigma-Beta qEEG signature with EFV.
Conclusions: A highly conserved EFV qEEG signature between rats, monkeys and humans makes this novel translational qEEG biomarker potentially useful for rapidly assessing the likelihood of CNS AEs in NNRTI drug development. The animal qEEG signal strength appeared to parallel the time course of reported clinical CNS AEs. Clinical studies of new NNRTIs may benefit from using qEEG to identify CNS adverse effect risk.